鉅細胞動脈炎治療市場規模、佔有率和成長分析：按治療方法、給藥途徑、疾病嚴重程度、最終用戶和地區分類 - 2026-2033 年行業預測

2024年全球鉅細胞動脈炎治療市值為2.352億美元，預計將從2025年的2.4578億美元成長到2033年的3.4953億美元。預測期（2026-2033年）的複合年成長率預計為4.5%。

由於人口老化和治療方案的進步，全球鉅細胞動脈炎 (GCA) 治療市場正經歷顯著成長，這表明治療方案正從傳統的高劑量糖皮質激素轉向創新、可減少類固醇用量的生物製藥，例如白細胞介素-6 抑製劑。這種轉變滿足了對有效治療方法的迫切需求，這些治療能夠最大限度地減少全身併發症並預防不可逆的視力喪失。隨著臨床醫生採用這些標靶治療，真實世界臨床數據證實，類固醇相關不利事件的發生率下降，減輕了醫院的負擔，並提高了生物製藥的報銷率。此外，血管成像技術和早期診斷的進步正在最佳化患者群體，而生物相似藥和口服製劑的推出則促進了價格競爭。這些因素共同作用，提高了成熟市場和新興市場的治療可及性，從根本上重塑了治療模式。

全球鉅細胞動脈炎治療市場促進因素

全球鉅細胞動脈炎治療市場正受到生物製藥已被證實能夠改善症狀控制並有效控制疾病。這一趨勢促使專科醫生更多地採用生物製劑，並延長患者的治療療程。因此，對已通過核准治療方法的需求不斷成長，促使供應商加大生產和分銷投入，同時也刺激了下一代分子藥物的競爭性研發。臨床醫生和患者對長期治療信心的增強正在深化市場，促使支付方和醫療保健系統考慮擴大保險覆蓋範圍，並透過既定的治療路徑推動市場整體擴張。

全球鉅細胞動脈炎治療市場的限制因素

全球鉅細胞動脈炎治療市場面臨嚴峻挑戰，這主要是由於許多創新治療方法的初始治療和持續治療費用高昂。這些經濟負擔加重了患者的經濟壓力，並加劇了醫療預算緊張，導致支付方實施限制性醫療保險政策並要求進行繁瑣的預先核准流程。這些報銷難題使得臨床醫生在開立昂貴治療方法時猶豫不決，轉而選擇更傳統的治療方法。這種情況阻礙了資源匱乏地區市場的滲透，並限制了患者獲得持續治療的機會。因此，需求有限以及不同醫療體系間治療資源分配不均嚴重阻礙了整體市場成長和先進治療方法的普及應用。

全球鉅細胞動脈炎治療市場趨勢

全球鉅細胞動脈炎治療市場正經歷著一場變革，生物製藥和生物相似藥的激增推動了這一趨勢，為醫療服務提供者和患者拓展了治療選擇。隨著企業採取創新的商業策略，促進與支付方的合作並加強患者支持舉措，這一趨勢正在提高藥物的可及性，並促使這些治療方法被納入處方藥目錄。製造商日益注重高效生產和穩定供應，以滿足不斷成長的需求。對真實世界證據的日益重視，以及對醫生教育的加強，正在導致治療方案的差異化和競爭格局的加劇。這推動了創新的給藥模式、用藥依從性計劃以及在多學科醫療機構中進行的綜合疾病管理的發展。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

市場考察

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場吸引力指數
• PESTEL 分析
• 監理情勢

全球鉅細胞動脈炎治療市場規模：依治療方法及複合年成長率分類（2026-2033 年）

• 皮質類固醇
  • 口服類固醇
  • 注射用皮質類固醇
• 生物製藥
  • IL-6抑制劑
  • 抗TNF製劑

全球鉅細胞動脈炎治療市場規模：依給藥途徑及複合年成長率分類（2026-2033 年）

• 口服
• 腸外給藥

全球鉅細胞動脈炎治療市場規模：依疾病嚴重程度及複合年成長率分類（2026-2033 年）

• 輕症病例
• 重症病例

全球鉅細胞動脈炎治療市場規模：按最終用戶和複合年成長率分類（2026-2033 年）

• 醫院
• 專科診所

全球鉅細胞動脈炎治療市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 2023-2025年營收年比比較

主要企業簡介

• Genentech
• AstraZeneca
• Novartis
• Pfizer
• Roche
• Bristol-Myers Squibb
• AbbVie
• GSK
• Merck & Co.
• Boehringer Ingelheim
• Sanofi
• Takeda Pharmaceuticals
• Eli Lilly and Company
• Amgen
• Bayer
• Regeneron Pharmaceuticals
• UCB
• Gilead Sciences
• Horizon Therapeutics
• Mallinckrodt Pharmaceuticals

結論與建議

Global Giant Cell Arteritis Treatment Market size was valued at USD 235.2 Million in 2024 and is poised to grow from USD 245.78 Million in 2025 to USD 349.53 Million by 2033, growing at a CAGR of 4.5% during the forecast period (2026-2033).

The Global Giant Cell Arteritis (GCA) Treatment Market is experiencing significant growth due to an aging demographic and advancements in therapeutic options, signaling a shift from traditional high-dose glucocorticoids to innovative, steroid-sparing biologics like interleukin-6 inhibitors. This transition addresses the urgent need for effective therapies capable of minimizing systemic complications and preventing irreversible vision loss. As clinicians adopt these targeted treatments, real-world evidence shows decreased rates of steroid-related adverse effects, reducing hospital burdens and encouraging payer reimbursement for biologics. Furthermore, improvements in vascular imaging and early diagnosis are optimizing patient volumes, while the introduction of biosimilars and oral agents is creating competitive pricing dynamics. Collectively, these factors enhance treatment accessibility in both established and emerging markets, fundamentally reshaping the therapeutic landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Giant Cell Arteritis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Giant Cell Arteritis Treatment Market Segments Analysis

Global giant cell arteritis treatment market is segmented by treatment type, administration route, disease severity, end users and region. Based on treatment type, the market is segmented into Corticosteroids and Biologics. Based on administration route, the market is segmented into Oral Administration and Parenteral Administration. Based on disease severity, the market is segmented into Mild Cases and Severe Cases. Based on end users, the market is segmented into Hospitals and Specialty Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Giant Cell Arteritis Treatment Market

The Global Giant Cell Arteritis Treatment market is significantly driven by the growing clinical inclination towards biologic agents, recognized for their ability to improve symptom control and manage the disease effectively. This trend leads to increased adoption among specialists and extends treatment durations for patients. Consequently, there is a rising demand for approved therapies, prompting suppliers to invest in production and distribution while encouraging the competitive development of next-generation molecules. Enhanced confidence among clinicians and patients in long-term therapy deepens the market, pushing payers and healthcare systems to explore wider coverage options, thereby facilitating overall market expansion through established treatment pathways.

Restraints in the Global Giant Cell Arteritis Treatment Market

The Global Giant Cell Arteritis Treatment market faces significant challenges due to high acquisition and ongoing management costs associated with many innovative therapies. These financial burdens create affordability issues for patients and strain healthcare budgets, prompting payers to implement restrictive coverage policies and necessitate extensive prior authorization processes. Such reimbursement difficulties deter clinicians from prescribing expensive treatments, favoring more traditional therapies instead. This scenario hinders market penetration in resource-limited environments and restricts patients' access to continuous treatment. Consequently, the limited demand and inconsistent access throughout various healthcare systems substantially impede overall market growth and the adoption of advanced therapies.

Market Trends of the Global Giant Cell Arteritis Treatment Market

The Global Giant Cell Arteritis Treatment market is witnessing a transformative shift driven by the proliferation of biologics and biosimilars, enhancing therapeutic options for both healthcare providers and patients. This trend promotes accessibility and encourages the inclusion of these treatments in formularies, as companies adopt innovative commercial strategies that foster collaborations with payers and bolster patient support initiatives. Manufacturers are advancing their focus on efficient production and consistent supply to meet growing demand. The emphasis on real-world evidence, alongside enhanced physician education, distinguishes treatment options and sparks competitive dynamics that promote innovative delivery models, adherence programs, and comprehensive disease management in multidisciplinary care settings.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Giant Cell Arteritis Treatment Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Corticosteroids
  • Oral Corticosteroids
  • Injectable Corticosteroids
• Biologics
  • IL-6 Inhibitors
  • Anti-TNF Agents

Global Giant Cell Arteritis Treatment Market Size by Administration Route & CAGR (2026-2033)

• Market Overview
• Oral Administration
• Parenteral Administration

Global Giant Cell Arteritis Treatment Market Size by Disease Severity & CAGR (2026-2033)

• Market Overview
• Mild Cases
• Severe Cases

Global Giant Cell Arteritis Treatment Market Size by End Users & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics

Global Giant Cell Arteritis Treatment Market Size & CAGR (2026-2033)

• North America (Treatment Type, Administration Route, Disease Severity, End Users)
  • US
  • Canada
• Europe (Treatment Type, Administration Route, Disease Severity, End Users)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Administration Route, Disease Severity, End Users)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Administration Route, Disease Severity, End Users)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Administration Route, Disease Severity, End Users)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Genentech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Horizon Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations